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Background: Breast cancer arising within a fibroadenoma (BcaFad) is rare; the rate varies from 0.002% to 0.125% in
fibroadenoma specimens. Owing to its rarity, the clinicopathologic feature and treatment principle of BcaFad is still
not clear. Therefore, the aim of this study was to perform a collective analysis of case reports in the literature to
identify the characteristics and optimal treatment for BcaFad.
Methods: We analyzed an aggregated sample of 30 patients with BcaFad from case reports in the literature (n =24
cases) and our present study (n =6 cases). We collected and analyzed the clinicopathologic features and prognoses
of patients with BcaFad, as well as treatments they received.
Results: The patients’ mean age at diagnosis was 46.9 years. Twenty BcaFad patients (66.7%) received breast-conserving
surgery (BCS), and nine other patients (30.0%) were treated with mastectomy. The rate of lymph node metastasis
in BcaFad patients was 23.8%. The breakdown of the histological types of BcaFad was invasive ductal carcinoma
(53.3%), followed by ductal carcinoma in situ (23.3%), lobular carcinoma in situ (16.7%) and invasive lobular carcinoma
(13.3%). More than half of patients with positive hormone receptor status received hormone therapy. Most BcaFad
patients with lymph node metastases received chemotherapy, and 20.0% of BcaFad patients treated with BCS received
further radiotherapy. Only one patient had recurrence after surgery, and another had lung metastasis when diagnosed
with BcaFad.
Conclusions: Most BcaFad patients could be managed by BCS. Adjuvant radiotherapy could be performed, but was
not mandatory. Chemotherapy should be considered as a treatment option in the presence of lymph node metastasis.
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Fibroadenoma is the most common cause of discrete
breast lumps in young females [1,2] and occurs in 25% of
asymptomatic women. Benign, asymptomatic fibroaden-
omas usually can be managed with nonoperative follow-up
[3-5]. Symptomatic, progressively enlarging masses or atyp-
ical presentations, however, may warrant surgical excision.* Correspondence: 143809@cch.org.tw
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unless otherwise stated.Although very rare, breast cancer arising within fibro-
adenoma (BcaFad) can still be found. The incidence of
BcaFad ranges from 0.125% to 0.02%, according to dif-
ferent reports [6-8]. In such circumstances, carcinomas
in situ (66.9% lobular carcinoma in situ (LCIS) and
12.4% ductal carcinoma in situ (DCIS)) are found to be
more common than invasive carcinomas (11% invasive
ductal carcinoma (IDC) and 3.4% invasive lobular car-
cinoma (ILC)) [9]. The optimal management of patients
with BcaFad is still not clear. Little information is avail-
able in current breast cancer management consensus
guidelines [10-13]. It is unknown whether such patients
should be treated similarly to those with breast cancer.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Flowchart of the search strategy. We initially identified
861 articles in the databases searched according to the keywords
used. We excluded 801 articles after title screening because they did
not mention fibroadenoma-related carcinoma, leaving 60 articles
retrieved that described a significant relationship between fibroadenoma
and carcinoma. We excluded 22 articles for lack of case details, even in
the abstracts; 5 articles for no case data in the main text; 3 articles
for focusing on other rare cancers linked to fibroadenoma; and 9
articles because they were case analyses or reviews. Thus, 24 cases
from 21 studies were included, together with our 6 cases, which
gave us a total of 30 cases for the final analysis.
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vidual medical institutions have very little experience in
treating these patients. Therefore, a collective case study
is needed for more information about the optimal man-
agement of BcaFad. In this article, we present our ex-
perience with six BcaFad cases and used a systematic
literature review process to find some characteristics of
and hints for the optimal care of these patients.
Methods
To further elucidate the characteristics and optimal man-
agement of patients with BcaFad, we performed a collective
analysis of case reports in the literature and our six cases.
The literature review was performed through PubMed
searches to collect English-language articles about BcaFad
published between January 1986 and January 2013. The
keywords used in the search use were “fibroadenoma”,
“carcinoma”, “breast”, “ductal” and “lobular”.
The literature search was limited to studies focused on
BcaFad with descriptions of diagnosis and/or treatment.
The investigated parameters included age, gender, tumor
size, diagnostic image, operation method, histology, hor-
mone receptor status (including estrogen receptor (ER)
and progesterone receptor (PR)), Human epidermal growth
factor receptor 2 (HER2) status, chemotherapy and radi-
ation therapy. The searches were limited to human studies.
Articles were excluded if they did not present BcaFad, pa-
tient information or treatment details. Articles published in
any language other than English were also excluded.
Demographic data collected and analyzed included age,
gender, size of the primary lesion, duration of follow-up,
image findings, fine-needle aspiration cytology or core-
needle biopsy results, pathology, operation method, postop-
erative therapy and recurrence or metastasis of the tumor.
Results
In our literature review, we collected 24 cases with de-
tailed information from 21 English-language articles.
After combining these with our 6 cases, the study popu-
lation comprised 30 BcaFad patients (Figure 1 and
Table 1). All of the patients were female, and their mean
age at diagnosis was 46.9 years old (range, 27 to 80 years
old). The mean duration from the finding of fibroaden-
oma to surgical excision was 61.2 months (range, 0.5 to
600 months). The mean tumor size of the fibroadenoma
was 2.46 cm (range, 0.8 to 5.1 cm). Most of the cancers
found inside the breast fibroadenoma were in situ car-
cinoma or early breast cancer with minimal or small
tumor size. The distribution of tumor locations was the
right side (53.3%), followed by the left side (40.0%) and
bilateral breast (3.3%). The clinicopathologic data of
these 30 patients are summarized in Table 1.
Twenty (66.7%) of thirty patients with BcaFad received
breast-conserving surgery (BCS), and nine other patients(30.0%) received mastectomies. One (patient 26) of these
nine mastectomy patients received immediate breast re-
construction (Figure 2). Furthermore, five (23.8%) of
twenty-one patients with the diagnosis of lymph node
status had lymph node metastasis. Most patients were
diagnosed with IDC (16 cases, 53.3%), followed by DCIS
(7 cases, 23.3%), LCIS (5 cases, 16.7%) and ILC (4 cases,
13.3%) (Table 2). Among these patients, only one patient
(patient 2) had both LCIS and IDC and another (patient 5)
had both DCIS and LCIS. The TNM stages recorded
were major in TisN0M0, T1aN0M0 stage to T1bN0M0.
A T1aN1M0 tumor was also noted.
Regarding hormone receptor status and HER2 status,
there were only 16 patients (53.3%) with data mentioned
about ER and PR status. Eleven (68.8%) of these sixteen
patients had ER + breast cancer, and ten patients (62.5%)
had PR + cancer. Of ten patients with known HER2 sta-
tus, only one patient (10.0%; patient 16) was found to
have HER2-overexpressing breast cancer. Among 11 pa-
tients with hormone receptor–positive BcaFad, 6 pa-
tients (54.5%) received tamoxifen treatment. Four (80%)
of five patients with lymph node metastasis received
chemotherapy.
Nine patients were treated with mastectomy, and an-
other twenty patients were treated with BCS. However,
only four (20.0%) of the twenty patients who underwent
BCS received radiotherapy [15,19,25]. Patient 17 received
radiotherapy to the chest wall following a mastectomy
Table 1 Demographic data from identified studies in the literature and our casesa
Patient Study Age
(yr)




Surgery LN dissection LN metastasis Receptor
status
C/T H/T R/T Outcome
1 Kurosumi et al., 1994 [14] 42 2 × 3 21 IDC Ex A
2 Sarela et al., 1995 [15] 56 2 × 3 2 LCIS + IDC MT A P
3 Shah et al., 1999 [16] 45 2.5 × 2 3 LCIS TisN0M0 Ex N
4 Yano et al., 2001 [17] 54 2 ILC TisN0M0 Ex A N
5 Kuijper et al., 2002 [18] 46 Multiple DCIS + LCIS TisN0M0 MT
6 Abe et al., 2004 [19] 42 5.1 × 4.4 60 IDC MT A P ER−PR+ Yes Yes No
7 Stafyla et al., 2004 [20] 27 3.4 LCIS TisN0M0 Ex N
8 Shin et al., 2006 [21] 51 1.5 × 1 12 IDC MT S N ER+PR+
9 Yuen et al., 2007 [22] 39 1.1 ILC BCS
10 Yuen et al., 2007 [22] 45 0.8 ILC BCS
11 Borecky and Rickard, 2008 [23] 64 1.2 IDC T1bN0M0 BCS S N ER+PR+
12 Borecky and Rickard, 2008 [23] 80 4.5 600 IDC BCS S N
13 Borecky and Rickard, 2008 [23] 53 1.7 12 DCIS TisN0M0 Ex S N
14 Gashi-Luci et al., 2009 [24] 39 2.6 × 1.6 IDC MT A N ER−PR− R
HER2−
15 Khandelwal et al., 2009 [25] 35 2 × 3 2 IDC BCS A P ER+PR+ Yes Yes Yes
HER2−
16 Iyengar et al., 2009 [26] 43 1.8 24 IDC MT ER−PR−
HER2+
17 Rao et al., 2010 [27] 30 4 × 2 1 IDC MT A P ER−PR− Yes No Yes
HER2−
18 Petersson et al., 2010 [28] 49 3 48 IDC Ex S N ER+PR+
HER2−
19 Kato et al., 2011 [29] 42 1.5 DCIS TisN0M0 BCS S N
20 Ooe et al., 2011 [30] 46 2.4 × 1.7 60 DCIS TisN0M0 BCS S N ER+PR+ No Yes Yes
21 Tajima et al., 2011 [31] 60 1.9 × 1.6 3 ILC BCS ER+PR+
HER2−
22 Abu-Rahmeh et al., 2012 [32] 69 5 180 IDC Lung
metastasisb
23 Jahan et al., 2012 [33] 55 5 × 4 × 3 240 IDC MT




















Table 1 Demographic data from identified studies in the literature and our casesa (Continued)
25 Present study 39 2.7 × 2.7 24 IDC T1aN0M0 BCS S N ER+PR+ No Nr Nr
HER2−
26 Present study 31 3.5 × 3.4 84 IDC T1aN1M0 MT A P ER+PR+ Yes Yes No
HER2−
27 Present study 30 1.5 × 1.4 DCIS TisN0M0 BCS ER+PR+ No Yes No
HER2−
28 Present study 63 1.2 0.5 DCIS TisN0M0 BCS S N ER+PR+ No Yes Yes
HER2−
29 Present study 48 0.9 3 DCIS TisN0M0 Ex S N No No No
30 Present study 40 0.6 0 IDC T1bN0M0 MT S N ER +PR− No Yes No
aA, Axillary lymph node dissection level I/II/III; B, Benign; C/T, Chemotherapy; ER, Estrogen receptor; Ex, Excision; HER2, Human epidermal growth factor receptor 2 ; H/T, Hormone therapy; LN, Lymph node; M,





















Figure 2 Postoperative photograph of patient 26. This patient
had centrally located breast cancer arising from a fibroadenoma
diagnosed before surgery. She was treated with endoscopically
assisted nipple-sparing mastectomy combined with immediate
breast reconstruction with a gel implant. Photograph was taken
3 months after surgery.
Table 2 Demographic and clinical featuresa
Characteristics (N =30) Data
Mean age (range), yr 46.9 (27 to 80)
Mean tumor size (range), cm 2.46 (0.8 to 5.1)
Female gender, n (%) 30 (100%)
Mean tumor follow-up duration (range) months 61.2 (0.5 to 600)











Operation method (N =30), n (%)
BCS 20 (66.7%)
Mastectomy 9 (30.0%)
No data 1 (3.3%)
Lymph node dissection (N =30), n (%)
Axillary clearance 8 (26.7%)
Sentinel lymph node dissection 11 (36.7%)
Not done 1 (3.3%)
No data 10 (33.3%)
Lymph node (N =30), n (%)
Metastasis 5 (16.7%)
Negative 16 (53.3%)
No data 9 (30.0%)
Receptor status
ER + (n =16) 11 (68.8%)
PR + (n =16) 10 (62.5%)
HER2+ (n =10) 1 (10.0%)
Further management
Chemotherapy (n =10) 4 (40.0%)
Hormone therapy (n =10) 6 (60.0%)
Radiation therapy (n =11) 5 (45.5%)
Outcome
Average follow-up (range), months 21.9 (5 to 59)
Recurrence (n =16) 1 (6.3%)
Distant metastasisc (n =16) 1 (6.3%)
aBCS, Breast-conserving surgery; DCIS, Ductal carcinoma in situ; ER, Estrogen
receptor; HER2, Human epidermal growth factor receptor 2; IDC, Invasive
ductal carcinoma; ILC, Invasive lobular carcinoma; LCIS, Lobular carcinoma in
situ; PR, Progesterone receptor; TNM, Tumor, node, metastasis. bOne patient
had both LCIS and IDC, and another had both DCIS and LCIS. cDistant metastasis
was noted at cancer diagnosis.
Wu et al. World Journal of Surgical Oncology 2014, 12:335 Page 5 of 8
http://www.wjso.com/content/12/1/335performed for lymph node metastasis [27]. Of the four
BCS patients with IDC, only one (25.0%) received radi-
ation therapy. In addition, among six BCS patients with
DCIS, only two (33.3%) received radiotherapy. Of fifteen
patients with descriptions of outcome and distant metas-
tasis, only one (patient 22) was found to have lung metas-
tasis at diagnosis. Another patient (patient 14) had a local
recurrence 5 months after surgery.
Discussion
It is very unusual for a carcinoma of the breast to arise
within a fibroadenoma. In this report, we present our 6
cases together with 24 previously reported cases for a
collective case analysis. Among these 30 cases, the mean
age at diagnosis of BcaFad was 46.9 years, which was
older than that at diagnosis of benign fibroadenoma (age
range from 20s to 30s) [5,35]. The mean duration from
finding a fibroadenoma to surgical excision was 61.2 months
(range from 0.5 to 600 months). This long duration can be
explained by the large size of the breast tumors (mean
2.46 cm) in this group of patients. This tumor size refers to
the diameter of the fibroadenoma in which the malignant
component was identified. In our present study, most
BcaFads were predominantly found to be small cancers
in relatively large fibroadenomas. However, the tumor
size was not reported in most of the reviews we in-
cluded, so we could not present the actual pathologic
tumor size in each individual (Tables 1 and 2). Half of
the data did not contain details regarding TNM stage;
the other half were for stages TisN0M0, T1aN0M0,
T1bN0M0 and T1aN1M0. However, we could assume
that most of the limited data were for early breast can-
cer according to the descriptions of histology.
According to our collective case analysis, the major
histological type of BcaFad was IDC (53.3%), followed by
DCIS (23.3%), LCIS (16.7%) and ILC (13.3%) (Table 2).
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that BcaFads were mainly carcinomas in situ (66.9%
LCIS and 12.4% DCIS), followed by invasive carcinoma
(11% IDC and 3.4% ILC) [9]. This discrepancy might be
due to selection bias. Our present study is a collective
analysis of case reports in the literature. Patients with in-
vasive carcinoma inside fibroadenoma are rare and tend
to be presented as case reports. In our six cases, the can-
cerous parts of the tumors were limited within the capsule
of the underlying fibroadenoma without extension to per-
ipheral breast tissue. In those BcaFad with DCIS, the DCIS
was limited inside the fibroadenoma without invasion into
the adjacent nonfibroadenoma breast tissue. In the LCIS-
containing tumors, three patients had pure LCIS, one pa-
tient had both IDC and LCIS and two patients had both
ILC and LCIS. None of them were found to have bilateral
breast cancer. In our present analysis, we found that LCIS
may be associated with invasive breast cancer.
In this study, 20 (66.7%) of 30 patients with BcaFad
could be managed by BCS, and another 9 patients
(30.0%) received mastectomies. The treatment principle
for benign fibroadenomas is surgical excision with a thin
ring of benign breast tissue [5], and breast conservation
is usually feasible. BcaFad is usually found incidentally
during the pathologic check when the breast tumor is
being excised. This could explain why most of these pa-
tients (66.7%) received BCS as their surgical treatment.
This breast-conserving rate is compatible with the re-
ported data (19.6-58.0%) in the management of breast
cancer with the same tumor size in the NASBP B-06
trial (National Surgical Adjuvant Breast and Bowel Pro-
ject) and the National Cancer Database in the United
States [36,37].
Another reason for the high breast-conserving rate of
the patients in this group is that most fibroadenomas are
well-defined, with a “capsule” [2,5]. If the initial resection
margin is free of cancer or only LCIS is inside the fibro-
adenoma, then a tumorectomy or lumpectomy alone may
be sufficient [15,25,38]. These facts could explain why the
high rate of patients with BcaFad received BCS in this
study. If the resection margin is involved or close, how-
ever, then a further wide excision may be needed [7].
Mastectomy (30.0% in this study) may still be needed in
some circumstances—usually in large, multifocal or
central located tumor [39]. One of our six patients (patient
26) received an endoscopically assisted, nipple-sparing
mastectomy combined with immediate breast reconstruc-
tion using a gel implant because of the large size and cen-
tral location of the breast tumor (Figure 2). Owing to the
favorable prognosis, mastectomy with immediate breast
reconstruction can be considered in patients with BcaFad
when a mastectomy is needed.
Radiotherapy can effectively reduce local recurrence,
and this reduction in disease relapse may translate toprolonged overall survival [11,12,40]. Nowadays, there is
an established rule that, in order to decrease the risk of
local recurrence, radiotherapy should be delivered to
breast cancer patients receiving BCS [10,13]. Should pa-
tients with BcaFad have to receive radiotherapy after
partial mastectomy? Tiu et al. [41] stated that BcaFad
behaves like breast cancer at the same stage and that
therefore the treatment should follow the same modality.
However, only four (20.0%) of the BCS patients received
radiotherapy according to our collective case analysis
[15,19,25]. Of four BCS patients with IDC, only one pa-
tient (25.0%; patient 15) received radiation therapy. In
addition, among six BCS patients with DCIS, only two
(33.3%) received radiotherapy.
According to our collective case analysis in this study,
it seemed as though not all surgeons agreed that radio-
therapy should be delivered to patients with BcaFad after
BCS. To date, to our knowledge, no randomized con-
trolled trials or large cohort studies have been conducted
to answer this question. According to our literature re-
view (Figure 1), fewer than 250 patients with BcaFad
have been reported to date, and only 8 of them were re-
ported to have received radiotherapy [14,19,25,27,30].
Whether radiotherapy is necessary for BcaFad patients
after BCS is still unknown; more solid evidence is
needed to establish the role of radiotherapy for this par-
ticular group of patients. To the best of our knowledge,
radiotherapy seems optional rather than mandatory for
BcaFad patients after partial mastectomy.
Owing to the limitations of a literature review, hormo-
nal and HER2 receptor status was incompletely reported.
In our collective case analysis, the incidence of hormone
receptor–positive BcaFad was 68.8% ER + and 62.5% PR+,
which is compatible with of the incidence in common
types of breast cancer (range, approximately 60% to 90%)
[42,43]. However, the rate of HER2 overexpression was
only 10.0%, which is a little lower than that of com-
mon types of breast cancer (approximately 15% to
25%) [44-46].
According to reports in the literature, most BcaFad
cases are carcinoma in situ (79.3%), and less than 15% are
invasive carcinomas [9]. BcaFad with lymph node metasta-
sis is unusual, but can still occur [15,19,25,27,47,48]. A
sentinel lymph node biopsy should be performed if there
is a pathologic confirmation of the presence of invasive
carcinoma of BcaFad. Furthermore, axillary lymph node
dissection should be performed in the presence of lymph
node metastasis. Lymph node metastasis, rather than
tumor size or hormone status, is the main concern under-
lying the use of chemotherapy for patients with BcaFad
[19,25,27,49].
The prognosis for patients with BcaFad was reported
to be more favorable than that in other common types
of breast cancer [19,25]. In our collective case analysis,
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sults, 1 patient (6.67%, patient 14) had local recurrence
5 months after surgery [24] and another (patient 22) was
found to have lung metastasis [32] when diagnosed with
BcaFad. Death caused by BcaFad was uncommon, but
still can occur in cases of invasive carcinomas at a late
stage [50,51].
Conclusions
BcaFad is an infrequent malignancy and carries a favor-
able prognosis. Most BcaFads can be managed with
BCS, and radiotherapy can be delivered optionally even
when patient has undergone BCS. A sentinel lymph
node biopsy should be performed if invasive carcinoma
is present. In the presence of lymph node metastasis,
chemotherapy should be considered to prevent distant
metastasis.
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